Onconetix, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Onconetix, Inc. (ONCO) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 313 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-06-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2025-06-02
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2024-09-30 was -12.19K shares.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2023-12-31 was 81.25K shares.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 313.00 shares, a 99.87% decline from fiscal 2023.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 250.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -12.19K shares derived: sum of 2 quarters · filed 2025-06-02 | 313.00 shares 10-K · filed 2025-06-02 | |
| 2024-09-30 | -12.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | 313.00 shares 10-Q · filed 2024-12-10 | ||
| 2024-06-30 | 12.50K shares 10-Q · filed 2024-08-29 | |||
| 2023-12-31 | 81.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | 250.11K shares 10-K · filed 2024-04-11 | ||
| 2023-09-30 | 168.86K shares 10-Q · filed 2023-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |